Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
Health care stocks were edging up Friday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up less than 0.1%. The iShares Biotechnology ETF (IBB)
Express News | Agenus Announces Extended BOT/BAL Therapy Yields Pronounced Tumor Reductions In Colon Cancer; Results From Investigator-Sponsored Trial Presented At 2024 ESMO Gastrointestinal Cancers Congress
Agenus Says Cancer Therapy Evaluation Program Is Accepting LOIs To Conduct Clinical Studies Using Botensilimab, Which Is Being Developed By CTEP As An Anticancer Agent In Collaboration With Company
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters
Express News | Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Market Report: Featuring Abeome, ABL Bio, Agenus, Akeso Biopharma, AnaptysBio, EpimAb Biotherapeutics, Immutep, Incyte and Y-Biologics
Agenus: Buell's Appointment Effective Immediately >AGEN
Agenus: Buell's Appointment Effective Immediately >AGEN
Agenus Appoints Jennifer Buell Chairman of Executive Council >AGEN
Agenus Appoints Jennifer Buell Chairman of Executive Council >AGEN
Express News | Agenus Announces Appointment of DR. Jennifer Buell to Its Board of Directors
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million. Concord Medical Services (NYSE:CCM) s
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial results.Core & Main posted quarterly earnings of 49 cents per share,
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 20 points on Tuesday.Shares of Saia Inc (NASDAQ:SAIA) rose sharply during today's pre-market trading session after the company reported
Agenus Announces Virtual Annual Shareholders Meeting
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Maintains Target Price $42
B.Riley Financial analyst Mayank Mamtani maintains $Agenus(AGEN.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 26.2% and a
Buy Rating Affirmed for Agenus Amid Promising Colorectal Cancer Study Results
H.C. Wainwright Maintains Agenus(AGEN.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright analyst Emily Bodnar maintains $Agenus(AGEN.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 38.3% and a tota
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Merus (MRUS) and Iovance Biotherapeutics (IOVA)
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial
Express News | FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy